DNA CHIP RESEARCH Stock

2397

JP3548590003

Biotechnology & Medical Research

Latest news : DNA CHIP RESEARCH

09/04/25	Mitsui Chemicals Completes Acquisition of DNA Chip Research	MT
07/04/25	Mitsui Chemicals, Inc. completed the acquisition of remaining 86.13% stake in DNA Chip Research Inc..	CI
04/02/25	Mitsui Chemicals Inc- Commencing Tender Offer For DNA Chip Research	RE
04/02/25	Mitsui Chemicals, Inc. proposed to acquire remaining 86.13% stake in DNA Chip Research Inc. for ¥6.4 billion.	CI
28/03/24	DNA Chip Research Inc. announced that it has received ¥269.99972 million in funding from Mitsui Chemicals, Inc.	CI
08/02/24	DNA Chip Research Inc. announced that it expects to receive ¥269.99972 million in funding from Mitsui Chemicals, Inc.	CI
21/02/23	DNA Chip Research Inc. announced that it has received ¥279.99974 million in funding from Mitsui Chemicals, Inc.	CI
23/01/23	DNA Chip Research Inc. announced that it expects to receive Ã‘279.99974 million in funding from Mitsui Chemicals, Inc.	CI
06/03/20	DNA Chip Research Inc. announced that it has received ¥3.92 million in funding from Daiwa Securities Co. Ltd.	CI
19/02/20	DNA Chip Research Inc. announced that it expects to receive ¥3.92 million in funding from Daiwa Securities Co. Ltd.	CI
08/12/14	DNA Chip Research Inc. announced that it has received ¥630.62 million in funding from Enplas Corporation.	CI
19/11/14	DNA Chip Research Inc. announced that it expects to receive ¥567.31 million in funding from Enplas Corporation.	CI

More news

Press Releases: DNA CHIP RESEARCH

20/08/20

Ricoh : Reference DNA plate for genetic testing in lung cancer Launch of RICOH Standard DNA Series EGFR mutation Type001

More press releases

Managers and Directors: DNA CHIP RESEARCH

Manager	Title	Age	Since
Ryo Matoba PSD	President	61	01/06/2010
Keiji Sato CTO	Chief Tech/Sci/R&D Officer	47	01/05/2015

Director	Title	Age	Since
Ryo Matoba BRD	Director/Board Member	61	01/06/2007
Masakazu Kuji BRD	Director/Board Member	69	-
Keiji Sato BRD	Director/Board Member	47	01/06/2019

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DNA CHIP RESEARCH	+0.18%	+0.18%	-	-	46.76M
LONZA GROUP AG	+1.59%	+8.79%	-5.48%	+2.49%	45.45B
REVOLUTION MEDICINES, INC.	+2.33%	+7.61%	+324.11%	+565.24%	36.09B
BEONE MEDICINES AG	-0.43%	+5.50%	+3.87%	+54.57%	30.81B
IQVIA HOLDINGS INC.	+2.53%	+8.76%	+17.05%	-13.29%	30.98B
CELLTRION, INC.	+7.60%	-1.09%	+12.49%	+20.82%	24.62B
ASCENDIS PHARMA A/S	+1.12%	+2.97%	-	-	14.78B
MEDPACE HOLDINGS, INC.	+3.28%	+12.19%	+62.65%	+129.55%	14.65B
EUROFINS SCIENTIFIC SE	+2.06%	+8.68%	+13.86%	+21.73%	13.3B
IONIS PHARMACEUTICALS, INC.	+0.80%	+2.97%	+93.04%	+93.04%	12.65B
Average	+2.04%	+5.97%	+65.20%	+109.27%	24.81B
Weighted average by Cap.	+2.21%	+6.19%	+70.41%	+123.04%

See all sector performances

DNA Chip Research Inc. is primarily engaged in DNA chip-related analysis and next-generation sequence related technology research business, and diagnostic business which is engaged in the sales of medical-related equipment centered on EGFR-NGS Check. The Contract Research segment is engaged in the microarray, next-generation sequencing experiment analysis to universities and research institutes, pharmaceutical and food companies. The Diagnostic segemnt utilizes genetic analysis technology to disseminate tests corresponding to social needs on personalized medicine and undiseased society. The main menu of the diagnostic business is EGFR-NGS Check. The Research and Development segment includes research on cancer diagnosis technology using next generation sequencer, as well as the development of RNA check.

Employees

Sector

Biotechnology & Medical Research

More about the company